Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for Fibrolamellar Carcinoma (FLC) patients. Fibrolamellar carcinoma (FLC) is a rare Liver Cancer that typically presents in young adolescents and young adults at a median age of 22 who have no history of liver disease. There is no clear standard of care for the disease, and in the setting of m...
Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=312660
This post first appeared on Why You Should Migrate To Magento 2 Services?, please read the originial post: here
